Summary This source did not publish a separate summary. Review SKILL.md before using the skill.
Infectious Disease Outbreak Intelligence
Rapid response system for emerging pathogens using taxonomy analysis, target identification, structure prediction, and computational drug repurposing.
KEY PRINCIPLES :
Speed is critical - Optimize for rapid actionable intelligenceTarget essential proteins - Focus on conserved, essential viral/bacterial proteinsLeverage existing drugs - Prioritize FDA-approved compounds for repurposingStructure-guided - Use NvidiaNIM for rapid structure prediction and dockingEvidence-graded - Grade repurposing candidates by evidence strengthActionable output - Prioritized drug candidates with rationaleEnglish-first queries - Always use English terms in tool calls (pathogen names, protein names, drug names), even if the user writes in another language. Only try original-language terms as a fallback. Respond in the user's language
When to Use
Apply when user asks:
"New pathogen detected - what drugs might work?"
"Emerging virus [X] - therapeutic options?"
"Drug repurposing candidates for [pathogen]"
"What do we know about [novel coronavirus/bacteria]?"
"Essential targets in [pathogen] for drug development"
"Can we repurpose [drug] against [pathogen]?"
Critical Workflow Requirements
1. Report-First Approach (MANDATORY)
Create the report file FIRST :
File name: [PATHOGEN]_outbreak_intelligence.md
Initialize with section headers
Add placeholder: [Analyzing...]
Progressively update as you gather data
Output separate files :
[PATHOGEN]_drug_candidates.csv - Ranked repurposing candidates[PATHOGEN]_target_proteins.csv - Druggable targets
2. Citation Requirements (MANDATORY) ### Target: RNA-dependent RNA polymerase (RdRp)
- **UniProt**: P0DTD1 (NSP12)
- **Essentiality**: Required for replication
- **Conservation**: >95% across variants
- **Drug precedent**: Remdesivir targets RdRp
*Source: UniProt via `UniProt_search`, literature review*
Phase 0: Tool Verification
Known Parameter Corrections Tool WRONG Parameter CORRECT Parameter NCBI_Taxonomy_searchnamequeryUniProt_searchnamequeryChEMBL_search_targetstargetqueryNvidiaNIM_diffdockprotein_fileprotein (content)
Workflow Overview Phase 1: Pathogen Identification
├── Taxonomic classification
├── Closest relatives (for knowledge transfer)
├── Genome/proteome availability
└── OUTPUT: Pathogen profile
↓
Phase 2: Target Identification
├── Essential genes/proteins
├── Conserved across strains
├── Druggability assessment
└── OUTPUT: Prioritized target list
↓
Phase 3: Structure Prediction (NvidiaNIM)
├── AlphaFold2/ESMFold for targets
├── Binding site identification
├── Quality assessment (pLDDT)
└── OUTPUT: Target structures
↓
Phase 4: Drug Repurposing Screen
├── Approved drugs for related pathogens
├── Broad-spectrum antivirals/antibiotics
├── Docking screen (NvidiaNIM_diffdock)
└── OUTPUT: Candidate drugs
↓
Phase 4.5: Pathway Analysis (NEW)
├── KEGG: Pathogen metabolism pathways
├── Essential metabolic targets
├── Host-pathogen interaction pathways
└── OUTPUT: Pathway-based drug targets
↓
Phase 5: Literature Intelligence (ENHANCED)
├── PubMed: Published outbreak reports
├── BioRxiv/MedRxiv: Recent preprints (CRITICAL for outbreaks)
├── ArXiv: Computational/ML preprints
├── OpenAlex: Citation tracking
└── OUTPUT: Evidence synthesis
↓
Phase 6: Report Synthesis
├── Top drug candidates
├── Clinical trial opportunities
├── Recommended immediate actions
└── OUTPUT: Final report
Phase 1: Pathogen Identification
1.1 Taxonomic Classification def identify_pathogen(tu, pathogen_query):
"""Classify pathogen taxonomically."""
# NCBI Taxonomy search
taxonomy = tu.tools.NCBI_Taxonomy_search(query=pathogen_query)
return {
'taxid': taxonomy.get('taxid'),
'scientific_name': taxonomy.get('scientific_name'),
'rank': taxonomy.get('rank'),
'lineage': taxonomy.get('lineage'),
'type': classify_type(taxonomy) # virus, bacteria, fungus, parasite
}
1.2 Related Pathogens (Knowledge Transfer) def find_related_pathogens(tu, taxid):
"""Find related pathogens for drug knowledge transfer."""
# Get family/genus level relatives
relatives = tu.tools.NCBI_Taxonomy_get_children(
taxid=taxid,
rank="genus"
)
# Find relatives with approved drugs
related_with_drugs = []
for rel in relatives:
drugs = tu.tools.ChEMBL_search_targets(
query=rel['scientific_name'],
organism_contains=True
)
if drugs:
related_with_drugs.append({
'pathogen': rel,
'drugs': drugs
})
return related_with_drugs
1.3 Output for Report ## 1. Pathogen Profile
### 1.1 Taxonomic Classification
| Property | Value |
|----------|-------|
| **Organism** | SARS-CoV-2 |
| **Taxonomy ID** | 2697049 |
| **Type** | RNA virus (positive-sense, single-stranded) |
| **Family** | Coronaviridae |
| **Genus** | Betacoronavirus |
| **Lineage** | Riboviria > Orthornavirae > Pisuviricota > Pisoniviricetes > Nidovirales |
### 1.2 Related Pathogens with Drug Precedent
| Relative | Similarity | Approved Drugs | Relevance |
|----------|------------|----------------|-----------|
| SARS-CoV | 79% genome | Remdesivir (EUA) | High |
| MERS-CoV | 50% genome | None approved | Medium |
| HCoV-229E | 45% genome | None specific | Low |
**Knowledge Transfer Opportunity**: SARS-CoV drug development data highly relevant.
*Source: NCBI Taxonomy, ChEMBL*
Phase 2: Target Identification
2.1 Essential Protein Identification def identify_targets(tu, pathogen_name):
"""Identify essential druggable targets."""
# Search UniProt for pathogen proteins
proteins = tu.tools.UniProt_search(
query=f"organism:{pathogen_name}",
reviewed=True
)
# Prioritize by essentiality and druggability
targets = []
for protein in proteins:
# Check for known drug interactions
chembl_target = tu.tools.ChEMBL_search_targets(
query=protein['gene_name']
)
targets.append({
'uniprot': protein['accession'],
'name': protein['protein_name'],
'function': protein['function'],
'has_drug_precedent': len(chembl_target) > 0,
'druggability': assess_druggability(protein)
})
return rank_targets(targets)
2.2 Target Prioritization Criteria Criterion Weight Description Essentiality 30% Required for replication/survival Conservation 25% Conserved across strains/variants Druggability 25% Structural features amenable to binding Drug precedent 20% Existing drugs for homologous targets
2.3 Output for Report ## 2. Druggable Targets
### 2.1 Prioritized Target List
| Rank | Target | UniProt | Function | Score | Drug Precedent |
|------|--------|---------|----------|-------|----------------|
| 1 | RdRp (NSP12) | P0DTD1 | RNA replication | 92 | Remdesivir |
| 2 | Main protease (Mpro) | P0DTD1 | Polyprotein cleavage | 88 | Nirmatrelvir |
| 3 | Papain-like protease | P0DTD1 | Polyprotein cleavage | 75 | GRL0617 (preclinical) |
| 4 | Spike protein | P0DTC2 | Host cell entry | 70 | Antibodies |
| 5 | Helicase (NSP13) | P0DTD1 | RNA unwinding | 65 | None approved |
### 2.2 Target Details
#### Target 1: RNA-dependent RNA polymerase (RdRp/NSP12)
| Property | Value |
|----------|-------|
| **UniProt** | P0DTD1 (polyprotein position 4393-5324) |
| **Length** | 932 amino acids |
| **Function** | Catalyzes RNA synthesis from RNA template |
| **Essentiality** | Absolute (no replication without RdRp) |
| **Conservation** | >99% across all SARS-CoV-2 variants |
| **Binding site** | Nucleotide binding pocket |
| **Drug precedent** | Remdesivir (FDA approved), Favipiravir |
*Source: UniProt, ChEMBL*
Phase 3: Structure Prediction
3.1 AlphaFold2 Structure Prediction (NVIDIA NIM) def predict_target_structure(tu, sequence, target_name):
"""Predict structure for target protein."""
# Use AlphaFold2 for high accuracy
structure = tu.tools.NvidiaNIM_alphafold2(
sequence=sequence,
algorithm="mmseqs2",
relax_prediction=False
)
# Parse pLDDT confidence
plddt_scores = parse_plddt(structure)
return {
'structure': structure['structure'],
'mean_plddt': np.mean(plddt_scores),
'high_confidence_regions': get_high_confidence(plddt_scores),
'predicted_binding_site': identify_binding_site(structure)
}
3.2 Structure Quality Assessment pLDDT Range Confidence Use for Docking >90 Very High Excellent 70-90 High Good 50-70 Medium Use caution <50 Low Not recommended
3.3 Output for Report ## 3. Target Structures
### 3.1 Structure Prediction Results
| Target | Method | Length | Mean pLDDT | Docking Ready |
|--------|--------|--------|------------|---------------|
| RdRp (NSP12) | AlphaFold2 | 932 aa | 91.2 | ✓ Yes |
| Mpro | AlphaFold2 | 306 aa | 93.5 | ✓ Yes |
| PLpro | AlphaFold2 | 315 aa | 88.7 | ✓ Yes |
### 3.2 RdRp Structure Quality
| Region | Residues | pLDDT | Functional Role |
|--------|----------|-------|-----------------|
| Palm domain | 582-620 | 94.2 | Catalytic site |
| Fingers domain | 397-581 | 91.8 | NTP entry |
| Thumb domain | 621-815 | 89.4 | RNA binding |
| Active site | D760, D761 | 96.1 | Catalysis |
**Docking Recommendation**: Structure suitable for docking; active site highly confident.
*Source: NVIDIA NIM via `NvidiaNIM_alphafold2`*
Phase 4: Drug Repurposing Screen
4.1 Identify Repurposing Candidates def get_repurposing_candidates(tu, target_name, pathogen_family):
"""Find approved drugs to repurpose."""
candidates = []
# 1. Drugs approved for related pathogens
related_drugs = tu.tools.ChEMBL_search_drugs(
query=pathogen_family,
max_phase=4
)
candidates.extend(related_drugs)
# 2. Broad-spectrum antivirals
antivirals = tu.tools.ChEMBL_search_drugs(
query="broad spectrum antiviral",
max_phase=4
)
candidates.extend(antivirals)
# 3. Drugs with known activity against target class
target_class_drugs = tu.tools.DGIdb_get_drug_gene_interactions(
genes=[target_name]
)
candidates.extend(target_class_drugs)
return deduplicate(candidates)
4.2 Docking Screen (NVIDIA NIM) def dock_candidates(tu, target_structure, candidate_smiles_list):
"""Dock candidate drugs against target."""
results = []
for smiles in candidate_smiles_list:
docking = tu.tools.NvidiaNIM_diffdock(
protein=target_structure,
ligand=smiles,
num_poses=5
)
results.append({
'smiles': smiles,
'top_score': docking['poses'][0]['confidence'],
'poses': docking['poses']
})
return sorted(results, key=lambda x: x['top_score'], reverse=True)
4.3 Output for Report ## 4. Drug Repurposing Screen
### 4.1 Candidate Identification
| Source | Candidates | FDA Approved |
|--------|------------|--------------|
| Related pathogen drugs | 12 | 8 |
| Broad-spectrum antivirals | 15 | 11 |
| Target class drugs | 8 | 5 |
| **Total unique** | **28** | **19** |
### 4.2 Docking Results (RdRp Target)
| Rank | Drug | Indication | Docking Score | Evidence |
|------|------|------------|---------------|----------|
| 1 | **Remdesivir** | COVID-19 | 0.92 | ★★★ FDA approved |
| 2 | **Favipiravir** | Influenza | 0.87 | ★★☆ Phase 3 COVID |
| 3 | **Sofosbuvir** | HCV | 0.84 | ★★☆ In vitro active |
| 4 | Ribavirin | RSV, HCV | 0.78 | ★☆☆ Mixed results |
| 5 | Molnupiravir | COVID-19 | 0.76 | ★★★ FDA approved |
### 4.3 Top Candidate: Remdesivir
| Property | Value |
|----------|-------|
| **Docking score** | 0.92 (excellent) |
| **Mechanism** | RdRp inhibitor (nucleotide analog) |
| **FDA status** | Approved for COVID-19 |
| **Clinical evidence** | ACTT-1: Reduced recovery time |
| **Binding mode** | Active site, chain termination |
*Source: NVIDIA NIM via `NvidiaNIM_diffdock`, ChEMBL*
Phase 4.5: Pathway Analysis (NEW)
4.5.1 Pathogen Metabolism Pathways def analyze_pathogen_pathways(tu, pathogen_name, pathogen_type):
"""Identify druggable metabolic pathways in pathogen."""
# KEGG pathogen pathways
pathways = tu.tools.kegg_search_pathway(
query=f"{pathogen_name} metabolism"
)
# Essential metabolic genes
essential_genes = tu.tools.kegg_get_pathway_genes(
pathway_id=pathways[0]['pathway_id']
)
# Host-pathogen interaction pathways
host_pathogen = tu.tools.kegg_search_pathway(
query=f"{pathogen_name} host interaction"
)
return {
'metabolic_pathways': pathways,
'essential_genes': essential_genes,
'host_interaction': host_pathogen
}
4.5.2 Output for Report ## 4.5 Pathway Analysis
### Pathogen Metabolic Pathways (KEGG)
| Pathway | Essentiality | Drug Targets |
|---------|--------------|--------------|
| Viral replication (ko03030) | Essential | RdRp, Helicase |
| Viral protein processing | Essential | Mpro, PLpro |
| Host membrane interaction | Essential | Spike, ACE2 |
### Druggable Pathway Targets
| Target | Pathway | Known Drugs | Evidence |
|--------|---------|-------------|----------|
| RdRp | Viral replication | Remdesivir | ★★★ |
| 3CLpro | Protein processing | Nirmatrelvir | ★★★ |
| PLpro | Protein processing | GRL-0617 | ★★☆ |
### Host-Pathogen Interaction Points
| Interaction | Host Protein | Pathway | Druggability |
|-------------|--------------|---------|--------------|
| Entry | ACE2 | Cell surface | ★★☆ |
| Fusion | TMPRSS2 | Protease | ★★★ |
| Replication | Host ribosomes | Translation | ★☆☆ |
*Source: KEGG, Reactome*
Phase 5: Literature Intelligence (ENHANCED)
5.1 Comprehensive Literature Search def comprehensive_outbreak_literature(tu, pathogen_name):
"""Search all literature sources for outbreak intelligence."""
# PubMed: Peer-reviewed
pubmed = tu.tools.PubMed_search_articles(
query=f"{pathogen_name} AND (outbreak OR treatment OR drug)",
limit=50,
sort="date"
)
# BioRxiv: CRITICAL for outbreaks - newest findings
biorxiv = tu.tools.BioRxiv_search_preprints(
query=f"{pathogen_name} treatment mechanism",
limit=20
)
# MedRxiv: Clinical preprints
medrxiv = tu.tools.MedRxiv_search_preprints(
query=f"{pathogen_name} clinical trial",
limit=20
)
# ArXiv: Computational/ML papers
arxiv = tu.tools.ArXiv_search_papers(
query=f"{pathogen_name} drug discovery",
category="q-bio",
limit=10
)
# Clinical trials
trials = tu.tools.search_clinical_trials(
condition=pathogen_name,
status="Recruiting"
)
# Citation analysis
key_papers = pubmed[:10]
for paper in key_papers:
citation = tu.tools.openalex_search_works(
query=paper['title'],
limit=1
)
paper['citations'] = citation[0].get('cited_by_count', 0) if citation else 0
return {
'pubmed': pubmed,
'biorxiv': biorxiv,
'medrxiv': medrxiv,
'arxiv': arxiv,
'trials': trials,
'key_papers': key_papers
}
5.2 Output for Report ## 5. Literature Intelligence
### 5.1 Published Literature (Peer-Reviewed)
| Topic | Papers | Key Finding |
|-------|--------|-------------|
| Treatment | 234 | Paxlovid remains effective |
| Resistance | 45 | Nirmatrelvir resistance mutations identified |
| Variants | 189 | XBB variants maintain drug sensitivity |
| Vaccines | 312 | Updated boosters protective |
### 5.2 Preprints (CRITICAL for Emerging Outbreaks)
**⚠️ Note**: Preprints are NOT peer-reviewed. Critical for rapid intelligence but use with caution.
| Source | Title | Posted | Key Finding |
|--------|-------|--------|-------------|
| BioRxiv | Novel RdRp inhibitor shows activity... | 2024-02-01 | New candidate |
| MedRxiv | Real-world effectiveness of... | 2024-01-28 | Paxlovid 85% effective |
| BioRxiv | Resistance mutations in... | 2024-01-25 | Monitor L50F mutation |
### 5.3 Computational/ML Preprints (ArXiv)
| Title | Category | Relevance |
|-------|----------|-----------|
| Deep learning for antiviral discovery | q-bio.BM | Drug design |
| Structure prediction for novel... | q-bio.BM | Target modeling |
### 5.4 Active Clinical Trials
| NCT ID | Phase | Drug | Status |
|--------|-------|------|--------|
| NCT05012345 | 3 | Ensitrelvir | Recruiting |
| NCT05023456 | 2 | VV116 | Recruiting |
| NCT05034567 | 2 | S-217622 | Active |
### 5.5 Citation Analysis (High-Impact Papers)
| PMID | Title | Citations | Year |
|------|-------|-----------|------|
| 33123456 | Remdesivir for COVID-19 | 5,234 | 2020 |
| 34234567 | Paxlovid Phase 3 results | 2,876 | 2022 |
*Source: PubMed, BioRxiv, MedRxiv, ArXiv, OpenAlex, ClinicalTrials.gov*
Report Template # Outbreak Intelligence Report: [PATHOGEN]
**Generated**: [Date] | **Query**: [Original query] | **Status**: In Progress
---
## Executive Summary
[Analyzing...]
---
## 1. Pathogen Profile
### 1.1 Classification
[Analyzing...]
### 1.2 Related Pathogens
[Analyzing...]
---
## 2. Druggable Targets
### 2.1 Prioritized Targets
[Analyzing...]
### 2.2 Target Details
[Analyzing...]
---
## 3. Target Structures
### 3.1 Prediction Results
[Analyzing...]
### 3.2 Binding Sites
[Analyzing...]
---
## 4. Drug Repurposing Screen
### 4.1 Candidate Drugs
[Analyzing...]
### 4.2 Docking Results
[Analyzing...]
### 4.3 Top Candidates
[Analyzing...]
---
## 5. Literature Intelligence
### 5.1 Recent Findings
[Analyzing...]
### 5.2 Clinical Trials
[Analyzing...]
---
## 6. Recommendations
### 6.1 Immediate Actions
[Analyzing...]
### 6.2 Clinical Trial Opportunities
[Analyzing...]
### 6.3 Research Priorities
[Analyzing...]
---
## 7. Data Gaps & Limitations
[Analyzing...]
---
## 8. Data Sources
[Will be populated...]
Evidence Grading Tier Symbol Criteria Example T1 ★★★ FDA approved for this pathogen Remdesivir for COVID T2 ★★☆ Clinical trial evidence OR approved for related pathogen Favipiravir T3 ★☆☆ In vitro activity OR strong docking + mechanism Sofosbuvir T4 ☆☆☆ Computational prediction only Novel docking hits
Completeness Checklist
Phase 1: Pathogen ID
Phase 2: Targets
Phase 3: Structures
Phase 4: Drug Screen
Phase 5: Literature
Phase 6: Recommendations
Fallback Chains Primary Tool Fallback 1 Fallback 2 NvidiaNIM_alphafold2alphafold_get_predictionNvidiaNIM_esmfoldNvidiaNIM_diffdockNvidiaNIM_boltz2Manual docking NCBI_Taxonomy_searchUniProt_taxonomyManual classification ChEMBL_search_drugsDrugBank_searchPubChem bioassays
Tool Reference 